Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 13/20 | 0.74 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.63 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.63 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.63 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.63 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.63 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.63 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.63 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.63 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.63 |
| ▸ | PRKX | P51817 | 1/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2574109 | 0.99 | ROCK1 (0.73) | ROCK1MAP2K1ROCK2PRKCDPRKACA | |
| SCHEMBL3221398 | 0.95 | ROCK1 (0.83) | ROCK1MAP2K1ROCK2PRKCDPRKACA | |
| Hydrochloric Acid SCHEMBL3233573 | 0.94 | ROCK1 (0.81) | ROCK1MAP2K1ROCK2PRKCDPRKACA | |
| SCHEMBL3228999 | 0.93 | ROCK1 (0.87) | ROCK1MAP2K1ROCK2PRKCDPRKACA | |
| SCHEMBL3231265 | 0.93 | ROCK1 (0.87) | ROCK1MAP2K1ROCK2PRKCDPRKACA | |
| SCHEMBL3229011 | 0.93 | ROCK1 (0.87) | ROCK1MAP2K1ROCK2PRKCDPRKACA | |
| Hydrochloric Acid SCHEMBL3232923 | 0.91 | ROCK1 (0.85) | ROCK1MAP2K1ROCK2PRKCDPRKACA | |
| Hydrochloric Acid SCHEMBL3230652 | 0.91 | ROCK1 (0.85) | ROCK1MAP2K1ROCK2PRKCDPRKACA | |
| Hydrochloric Acid SCHEMBL3230663 | 0.91 | ROCK1 (0.85) | ROCK1MAP2K1ROCK2PRKCDPRKACA | |
| SCHEMBL8938640 | 0.88 | ROCK1 (0.76) | ROCK1MAP2K1ROCK2PRKCDPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385047-B1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| EP-2385047-B1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| EP-1910333-B1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2013-05-22 | — | — | EP | disclosed |
| EP-1910333-B1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2013-05-22 | — | — | EP | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| EP-1910333-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | Sanofi-Aventis (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012421-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007012421-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | ROCK1 8/4885MAP2K1 1916/4885ROCK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.